CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Context Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.24−0.01 (-2.30%)
Close on Oct 19, 2026
- Market cap
- $22.69M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.2016 (−83.44%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $22.69M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.59
- Dividend yield
- –
- Free cash flow yield
- -149.95%
Fundamentals
- Net income
- -$45.96M
- EPS, diluted
- -$0.48
- Free cash flow
- -$34.03M
- Book value per share
- $0.40
- Diluted shares
- 95M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$48.73M
Net income
-$45.96M
EPS, diluted
-$0.48
Free cash flow
-$34.03M
Reported periodTrailing twelve months